The performance score is a known prognostic factor in patients with recurrent or metastatic SCCHN treated with EGFR-antibodies in combination with chemotherapy or chemotherapy alone.[7, 23, 24] Furthermore, in the SPECTRUM trial, in which patients were treated with cisplatin, fluoruracil and panitumuab, weight loss of more than 5% during the last 6 months and prior platinum chemotherapy were identified as independent negative prognostic factors. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.